Basf Aktiengesellschaft

Abbott Gmbh & Co Kg

Other

Warner-lambert Company

Basf Aktienegesellschaft

Bernd Janssen

Andreas Haupt

Andreas Kling

Hans-Heiner Wuest

Teresa Barlozzari

Thomas Zierke

Kurt Ritter

Wilhelm Amberg

Ernst Buschmann

Harald Bernard

Michael P Wachter

Stanley Charles Bell

William V Murray

Marco Thyes

Stefan Karbach

Eberhard Ammermann

Norbert Meyer

Ulrich Karl

Stefan Muller

Ernst-Heinrich Pommer

Lothar Janitschke

Bernd De Potzolli

Hans-Guenther Hege

Helmut Lietz

Martina Ullrich

Gisela Lorenz

Hubert Sauter

George R Pettit

Cynthia A Romerdahl

Gerhard Keilhauer

Hans-Gert Recker

Friedrich-Wilhelm Kohlmann

Wolfgang Heberle

Walter Wesenberg

Jurgen Weymann

Christian Griesinger

Michael Boretzky

Daniel Belik

Reiner Kober

Gerd Steiner

Rainer Seele

Michael D Williams

Fritz-Frieder Frickel

Horst Koenig

Jay Bradford Fell

Dagmar Klinge

Rainer Schlecker

Axel Nuerrenbach

Wolfgang Steglich

Charles J Stankovic

Sheryl Jeanne Hays

Timm Anke

Mark Stephen Plummer

Peter Scharwaechter

Kimberly Suzanne Para

William Glen Harter

Xiao-Dong Qian

Aurash B Shahripour

Stefan M&uuml;ller

Jayaram Kasturi Srirangam

Michael Connolly

Stefan Mueller

Paul Galatsis

Kieran P M Durkin

Jurgen Weyman

Monika De Arruda

Hans-Heiner Wuesi

James Knobelsdorf

Gerhard Laur

Beth Lunney

Jürgen Weymann

Hans H Wuest

Ulrich Traugott

Simon Robinson

The present invention provides antineoplastic peptides of formula I, wherein R, R, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.

Antineoplastic peptides

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,A-B-D-E-F-(G)-(K)-L&#x2003;&#x2003;(I),and acid salts thereof, wherein A, B, D, E, F, G and K are &#x3b1;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &#x3b2;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Dolastatin 15 derivatives

The present invention provides antineoplastic peptides of formula I,RRN&#x2014;CHX&#x2014;CO&#x2014;A&#x2014;B-D-E-(G)-Kwherein R, R, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,A-B-D-E-F-(G)-(K)-L &#x2003;&#x2003;(I),and acid salts thereof, wherein A, B, D, E, F, G and K are &#x3b1;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &#x3b2;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

The present invention provides antineoplastic peptides of formula I,RRN&#x2014;CHX&#x2014;CO-A-B-D-E-(G)-K Iwherein R, R, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,A-B-D-E-F-(G)-(K)-L,&#x2003;&#x2003;(I)and acid salts thereof, wherein A, B, D, E, F, G and K are &#x3b1;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &#x3b2;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1&#x3b2; converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure:and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

Arylsulfonamide ethers, and methods of use thereof

The present invention provides compounds of the formula

Dolastatin peptides

Compounds useful for the synthesis of dolastatin analogs

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I

The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,

Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities

Preparation of active peptides

The present invention provides anti-tumor peptides of Formula I,

Tetrapeptides as antitumor agents

Growing community of inventors

Ludwigshafen, Germany

Bernd Janssen